F. Hoffmann-La Roche AG
Molecular Biomarker Leader
Headquartered in Basel, Switzerland, Roche is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market. Roche employs roughly 65,000 people in 150 countries. The CNS group in Roche has expertise in the areas of Alzheimer’s disease, schizophrenia, depression, and imaging which spans from discovery where Roche scientists have made major advancements in identifying pathways involved in schizophrenia and depression to the clinic where innovative new first-in-class medications are being developed for these major psychiatric disorders. The CNS group at Roche is committed to contribute to the success of NEWMEDS by providing its expertise in several areas of interest including but not limited to: pharmaco MRI and preclinical studies where we will provide expertise in designing and performing experiments with animal models, PET ligand development where we will contribute to the development of novel radioligands through our expertise in several methods which include: synthesis of precursors, tritium radiolabeling, autoradiography, and in vivo binding. We will also contribute by providing genetic analysis including GWAS, CNV and transcriptional data and phenotypic characteristics from our clinical sample.